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Peroxisome proliferator-activated receptor-gamma (PPAR-g) is a pivotal key for
pro-inflammatory effect of leptin on human epithelial colonic cells
Abolhassani
1 M, Marie
1 JC, Ashktorab
2 H, Bado
1 A and Sobhani
1 I
1Department of liver and Gastroenterology, Henri Mondor Hospital Cre ´teil and INSERM U410, Bichat Hospital, Paris,
France;
2Medicine and Cancer Center, Howard University Hospital, Georgia, Washington, DC, USA
Leptin, the product of the ob gene, regulates food intake,
energy balance and lymphocyte functions. Receptor mu-
tated animals have reduced production of proinflammatory
cytokines. To analyze the direct effects of leptin (0.1 nM /1
mM) on cytokine production from colonic cells, we
examined pro-inflammatory (IL-8, MCP-1, IL-6 and TNF-
alpha) and anti-inflammatory (IL-10) cytokine production
in normal human colonic epithelial fresh cells and in colon
cancer cell lines (HT-29 and Caco-2) using an ELISA and the
Rnase Protection Assay (RPA). Leptin increased the release
of IL-8 and MCP-1 and slightly reduced IL-10 release, but
did not affect both basal-stimulated and LPS-stimulated IL-6
and TNF-alpha in the supernatant of confluent cells. Up to
24 h after cell exposure to leptin, IL-8 significantly
increased and IL-10 decreased, and these effects were dose
and time dependently documented in cancer cell lines
(HT29 and Caco2). To investigate the mechanisms of this
pro-inflammatory effect, by luciferase reporter gene assay,
we showed an increase in the activity of NF-kappaB in
response to leptin in a dose-dependent manner. This
activity was inhibited in IkappaB super-repressor trans-
fected cells as assessed by luciferase expression and IL-8
and MCP-1 production (ELISA and RPA). Furthermore,
PPAR-gamma was reduced after leptin treatment as as-
sessed by western blot while the addition of PPAR agonists
(Rosiglitazone and MCC-555) induced a decrease of IL-8
and MCP-1 expression, suggesting PPAR-gamma suppres-
sion is required for cytokine productions. The failure of the
PPAR-gamma antagonist (GW-9662) to inhibit cytokine
production and to alter NF-kappaB activity suggest that
PPAR-gamma suppression is required for cytokine produc-
tions. We demonstrate that leptin regulates pro-inflamma-
tory cytokine production by colonic epithelial cells via
PPAR-gamma modulation.
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55Anti-inflammatory potency of PPARg ligands in articular cells
Bianchi A, Moulin D, Boyault S, Poleni PE, Bordji K, Netter P, Jouzeau JY and Terlain B
UMR 7561 CNRS-UHP Nancy 1, Laboratoire de Physiopathologie et Pharmacologie articulaire, Faculte ´ de
Me ´decine */ BP 184, F-54505 Vandoeuvre les Nancy, France
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors belonging to the
nuclear receptor superfamilly. They regulate lipid metabo-
lism, glucose homeostasis, cell proliferation and differentia-
tion and are thought to modulate inflammatory responses.
We studied the expression of PPAR isotypes (a, b, g)i n
resident articular cells as well as the anti-inflammatory
potency associated with PPARg agonists. Most experiments
were performed on primary cultures of B synoviocytes (rat)
or chondrocytes (rat and human) stimulated with bacterial
endotoxin (LPS) or interleukin-1b (IL-1b), respectively. Our
results showed that all isotypes of these nuclear receptors
are constitutively expressed in chondrocytes and synovio-
cytes as well as in ‘articular’ adipocytes of the rat fat pad.
Inflammatory stimulus (IL-1b, LPS) decreased PPARg ex-
pression in all cell types whereas other isotypes remained
unaffected. Their stimulating effect on inflammatory
gene expression (mPGES, iNOS, COX-2, TNFa and IL-1)
and corresponding proteins or mediators was inhibited
unequally by natural (15d-PGJ2) or synthetic (Troglitazone,
Rosiglitazone) PPARg agonists.
At similar concentrations, the inhibitory potency of
glitazones was less than that observed with 15d-PGJ2
except for TNFa production in response to LPS in
synoviocytes. This result suggested strongly that the anti-
inflammatory potency of 15d-PGJ2 occurred independently
from PPARg activation. We demonstrated further that 15d-
PGJ2 interacted with the NF-kB pathway via several sites of
inhibition, mainly by decreasing IkBa phosphorylation and
IkBa degradation through the induction of stress proteins
(HSP). In contrast, the inhibitory effect of glitazones on
TNFa production by synoviocytes was PPARg dependent
and could be due to the induction of the SOCS-1
(Suppressor of Cell Signalling-1) protein.
These results show that 15d-PGJ2 inhibit effects of pro-
inflammatory cytokines in a PPARg-independent manner
whereas synthetic PPARg agonists inhibit cytokine produc-
tion in articular cells.
The PPAR-g agonist, Rosiglitazone, upregulates the receptor for advanced glycated
end-products (RAGE) in human macrophages
Ahluwalia MK, Roberts AW, Evans M, Webb R and Thomas AW
University of Wales Institute, School of Applied Sciences, Western Avenue, Llandaff Campus,
Cardiff CF5 2YB, UK
Thiazolinediones (PPAR-g agonists, which ameliorate in-
sulin resistance) have also been reported to possess anti-
inflammatory properties. One of the most important
inflammatory pathways in type 2 diabetes is the interaction
of advanced glycated end-products (AGEs) with receptor
for AGE (RAGE) in monocytes and macrophages, resulting
in induction of inflammatory mediators. In this study we
aimed to determine the effect of PPAR-g agonists on
expression of RAGE and subsequent AGE-induced TNFa
release in the human macrophage-like cell lines, MM6 and
differentiated THP1.
Simultaneous incubation of MM6 cells with Rosiglitazone
(2 /20 mM) and AGE (500 mg/ml) for 5 h significantly
reduced AGE-induced TNFa secretion (maximum 339 /3%,
p B/0.001). Paradoxically, if cells were pre-incubated with
Rosiglitazone (2 /20 mM) for 24 h prior to 5 h incubation
with AGE, TNFa release was elevated by 639 /4%
(p B/0.001). PPAR-g agonist significantly upregulated
RAGE expression in these cells (maximum 2.8-fold in-
crease, p B/0.05). Thus, the AGE-induced rise in TNFa
correlated with the PPAR-g agonist-dependent increase in
RAGE expression. The mechanism by which the PPAR-g
agonist upregulates RAGE has not yet been fully elucidated
but may possibly be due to PPAR-g-independent phosphor-
ylation events that result in the induction of RAGE-specific
transcription factors. We have confirmed these data
using the specific PPAR-g agonist, GW7845, and in THP1
cells.
Our data demonstrating a PPAR-g-dependent increase in
RAGE expression may initially appear to be a pro-
inflammatory event. However, RAGE expression in other
tissues may provide a favourable mechanism for the
removal of AGEs from the circulation and therefore a net
anti-atherogenic effect.
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macrophages through a peroxisome proliferator-activated receptor gamma-independent
process
Adeline Cheron, Julie Peltier, Joe ¨lle Perez, Agne `s Bellocq, Bruno Fouqueray and Laurent Baud
INSERM U489, Ho ˆpital Tenon, 4 rue de la Chine, 75020 Paris, France
15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ2) is in-
volved in the control of inflammatory reaction. We tested
the hypothesis that 15d-PGJ2 would exert this control in
part by modulating the sensitivity of inflammatory cells to
glucocorticoids. Human U 937 cells and mouse RAW 264.
Seven cells were exposed to 15d-PGJ2 and binding
5experiments were performed with [
3H]-dexamethasone
as a glucocorticoid receptor (GR) ligand. 15d-PGJ2 caused a
transient and dose-dependent decrease in [
3H]-dexametha-
sone-specific binding to either cell, through a decrease in
the average number of GR per cell without significant
modification of the Kd value. These changes were related
to functional alteration of the GR rather than to decrease in
GR protein. They did not require the engagement of
peroxisome proliferator-activated receptor gamma
(PPAR gamma), since the response to 15d-PGJ2 was
neither mimicked by the PPAR gamma agonist ciglitazone
nor prevented by the PPAR gamma antagonist BADGE. 15d-
PGJ2 altered GR possibly through the interaction of its
cyclopentenone ring with GR cysteine residues since
cyclopentenone ring per se could mimic the effect of 15d-
PGJ2 and modification of GR cysteine residues with
MMTS suppressed the response to 15d-PGJ2. Finally, 15d-
PGJ2-induced decreases in glucocorticoid binding to GR
resulted in parallel decreases in the ability of GR to
transactivate [GRE]2 TK-Luc and to reduce the expression
of monocyte chemoattractant protein-1 (MCP-1). Together,
these data suggest that 15d-PGJ2 limits glucocorticoid
binding and signalling in human and murine monocytes/
macrophages through a PPAR gamma-independent
and cyclopentenone-dependent mechanism. It provides a
way by which 15d-PGJ2 would exert pro-inflammatory
activities in addition to its known anti-inflammatory
activities.
PPARg promotes macrophage mannose receptor gene expression by IL-13: consequences
in the control of gastrointestinal candidosis in normal and immunodeficient
RAG-2
/ mice
Coste A, Authier H, Balard P, Cassaing S, Linas MD, Bernad J, Lepert JC, Dubourdeau M and Pipy B
EA 2405, INSERM IFR 31, Universite ´ Paul Sabatier, CHU Rangueil, 31403 Toulouse cedex 4, France
Effective host defense against microbial infection is char-
acterized by rapid recognition and clearance of the patho-
gen involving increased expression of the pattern-
recognition receptors. Thus, macrophage mannose recep-
tor (MMR) is implicated in the recognition of unopsonized
microorganisms, which as Candida albicans have man-
nose residues on the cell surface. MMR expression may be
critical in phagocytosis process, in host defense functions
and in antigen processing. MMR over-expression can be
modulated by Th2 cytokines such as interleukin-13 (IL-13).
The mechanisms involved in regulation of its expression
are little known. We demonstrate in murine macrophages
that IL-13 can positively regulate MMR surface expression
by controlling the production of PPARg endogenous
ligands, particularly 15d-PGJ2 via cPLA2 activation. This
regulation of MMR, which is also obtained with synthetic
PPARg ligands, is PPARg dependent. In parallel, this
signaling pathway promotes uptake and killing of Candida
via reactive oxygen intermediates production. In vivo study
on normal or immunodeficient RAG-2
 /  mice validates
that the PPARg ligands as IL-13 treatments significantly
decrease C. albicans infection in gastrointestinal tract. This
reduction of Candida colonization is correlated with the
increase of Candida phagocytosis and reactive oxygen
intermediate production of macrophages via MMR induc-
tion. These in vitro and in vivo observations show that
PPARg and the ligands of this nuclear receptor are involved
in the regulation of innate immune response in increasing
the expression of MMR. These results let us perceive the
possibility that PPARg ligands may be of therapeutic value
in human diseases due to the pathogens that are eliminated
by the MMR.
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acute and chronic inflammation
Cuzzocrea
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1Dipartimento Clinico e Sperimentale di Medicina e Farmacologia, Torre Biologica, Policlinico Universitario, 98123 Messina,
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2The William Harvey Research Institute, St Bartholomew’s and The Royal London School of Medicine, London, UK
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of
ligand-activated transcription factors that are related to
retinoid, steroid and thyroid hormone receptors. The PPAR-
g receptor subtype appears to play a pivotal role in the
regulation of cellular proliferation and inflammation. We
postulated that rosiglitazone, a synthetic PPAR-g-specific
agonist, and 15-deoxy-D
12,14PGJ2 (15d-PGJ2), which is a
metabolite of the prostaglandin D2, and functions as an
endogenous ligand for PPAR-g, would attenuate acute and
chronic inflammation. We have investigated the effects of
rosiglitazone and 15d-PGJ2 in animal models of acute and
chronic inflammation (carrageenan-induced pleurisy and
collagen-induced arthritis, respectively). We report here
that rosiglitazone given at (10, 30 or 100 mg/kg i.p., or at 30
mg/kg i.p every 48 h in the arthritis model) and 15d-PGJ2
(given at 10, 30 or 100 mg/kg i.p. in the pleurisy model or at
30 mg/kg i.p. every 48 h in the arthritis model) exerts potent
anti-inflammatory effects (e.g. inhibition of pleural exudate
formation, mononuclear cell infiltration, delayed develop-
ment of clinical indicators and histological injury) in vivo.
Furthermore, Rosiglitazone and 15d-PGJ2 reduced; (1) the
increase in the staining (immunohistochemistry) for
nitrotyrosine and poly (ADP-ribose) polymerase (PARP),
and (2) the expression of inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2) in the lungs
of carrageenan-treated mice and in the joints from col-
lagen-treated mice. To confirm that the observed anti-
inflammatory property of the two PPAR-g agonists was
related to the activation of the PPAR-g receptor we have
carried out a new set of experiments using a selective
antagonist for the PPAR-g (Bisphenol A Diglicydyl Ether).
This compound, given (1 mg/kg i.v.) 30 min before
rosiglitazone or 15d-PGJ2 was able to revert the beneficial
effect of the PPAR-g ligand in the acute model of
inflammation.
Taken together, our results clearly demonstrate that
rosiglitazone and 15d-PGJ2 treatment exerts a protective
effect and part of this effect may be due to inhibition of the
expression of adhesion molecules and peroxynitrite-related
pathways with subsequent reduction of neutrophil-
mediated cellular injury.
Impaired expression of the peroxisome proliferator activated receptor alpha during
hepatitis C virus infection
Se ´bastien Dharancy
1, Mathilde Malapel
1, Gabriel Perlemuter
2, Tania Roskams
3, Yang Cheng
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4, Filome ´na
Conti
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4Laboratoire de Biologie Cellulaire, Faculte ´ de Me ´decine Cochin Port-Royal, 75014 Paris, France;
5Institut de Ge ´ne ´tique et Biologie Mole ´culaire et Cellulaire (IGBMC), INSERM, CNRS, Universite ´ Louis Pasteur, 67404
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Background and aims: Liver inflammation and fibrosis are
common features in patients with chronic hepatitis C virus
(HCV) infection. Since the heterodimer peroxisome pro-
liferator activated receptor (PPAR)alpha/retinoid X receptor
(RXR) is expressed in the liver and is involved in the
regulation of metabolism and inflammation, we studied its
hepatic expression and function during liver injury in
patients with HCV infection.
Methods: PPAR alpha/RXR mRNAs were quantified in liver
biopsies of 46 untreated patients with HCV infection and
compared with 40 controls. Heterodimer levels were
analysed according to the intensity of liver inflammation/
fibrosis. To determine whether HCV may influence PPAR
alpha expression in the liver, we also quantified PPAR
alpha and its liver target gene CPT1A in human hepatocel-
lular carcinoma cell line stably expressing HCV core
protein.
Results: Hepatic levels of RXR mRNA were similar in pa-
tients and controls. Using real-time PCR and western blot,
levels of PPAR alpha and CPT1A mRNA and protein were
significantly lowered in the liver of untreated patients with
HCV infection compared with controls, and inversely asso-
ciated with inflammatory and fibrosis scores. Similarly, an
impaired expression of PPAR alpha and CPT1A mRNAs
were found in hepatocytes stably expressing HCV core pro-
teinandactivatedwiththePPARalphaligandfenofibricacid.
Conclusions: Impaired expression of the anti-inflammatory
nuclear receptor PPAR alpha in the liver of patients with
hepatitis C virus infection may be involved in the patho-
genesis of HCV infection. This decreased transcriptional
activity of PPAR alpha may be influenced at least in part by
HCV core protein expression. Taken together, these results
suggest that PPAR alpha activators may be an alternative to
the traditional therapeutic approaches of HCV-induced
liver injury.
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with ulcerative colitis: roles of the Toll-like receptor 4
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Background: The peroxisome proliferator-activated recep-
tor gamma is a nuclear receptor highly expressed in the
colon and playing a central role in the regulation of colitis
through attenuation of the NF-kB pathway.
1,2 NF-kB is a
transcription factor regulated by Toll-like receptors (TLRs),
which are receptors for bacteria. TLR-4 is overexpressed by
epithelial cells in patients with inflammatory bowel dis-
eases (IBD).
3
Aim: (1) To study the possible crosstalk between TLR-4 and
PPAR gamma and (2) to evaluate the expression and
genetic polymorphism of PPAR gamma in patients with
Crohn’s disease (CD) and ulcerative colitis (UC).
Methods: (1) Transfections of Caco-2 cells with TLR-4, PPAR
gamma or the response element of PPAR (PPRE) were used
to assess the regulation of PPAR gamma by TLR-4; (2) PPAR
gamma mRNA and protein were quantified by competitive
PCR, western blot and immunohistochemistry in peripheral
blood mononuclear cells (PBMC), healthy and inflamed
colon biopsies of 122 patients with IBD (53 UC and 69 CD)
compared with 60 controls. The polymorphism of the PPAR
gamma gene and promoter was studied in 53 patients with
UC compared with 1158 controls.
Results: (1) Activation of TLR-4 transfected Caco-2 cells with
LPS upregulated the expression of PPAR gamma and
activated the PPRE; (2) PPAR gamma concentrations were
similar in PBMC of patients with UC, CD and controls.
Expression of both PPAR gamma mRNA and protein was
significantly decreased in the healthy and inflamed colon
mucosa in UC as compared with CD and controls. No
mutation of the PPAR gamma gene or its promoter was
found in UC or controls.
Conclusion: PPAR gamma expression and activation is
regulated by the TLR-4 and may be a key regulator of
mucosal inflammation induced by bacteria. PPAR gamma
expression is dramatically decreased in the colonic mucosa
of patients with UC. A mucosal imbalance between TLR-4
and PPAR gamma may thus lead to colon inflammation
induced by flora in patients with UC.
ACKNOWLEDGEMENTS. The authors thank the
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des Maladies de l’Appareil digestif and the Fondation pour
la Recherche Me ´dicale for their support.
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A PPAR alpha-dependent pathway increases IL-1ra production and protect from IL-1beta
detrimental effects in articular chondrocytes
Mathias Franc ¸ois, Pascal Richette, Franc ¸ois Rannou, Lydia Tsagris and Marie-Therese Corvol
UMR-S 530 Inserm-Paris5, 45 rue des St Peres 75006 Paris, France
Cytokines, such as interleukin-1beta (IL-1beta), induce
cartilage degradation and inflammatory process via metal-
loproteinases (MMPs) and COX2 gene expression in
chondrocytes. We used Clofibrate (CloF), an activator of
peroxysome proliferator-activated receptor alpha (PPAR-
alpha), to assess the influence of PPAR-alpha on IL-1beta-
mediated gene expression. By using northern blot analysis,
electrophoretic mobility shift assay (EMSA) and transient
transfection assay PPAR-alpha was shown to be expressed
and functional in chondrocytes in vitro. CloF (50 /500 mM)
displayed concentration-dependent inhibitory effects on IL-
1beta-induced degradative and inflammatory markers.
CloF inhibited IL-1beta-induced decrease in
35S-sulfated
proteoglycan production. CloF also counteracted gelatino-
lytic activities and down-regulated MMP and COX2 mRNA
expression induced by IL-1beta. CloF maximized
the endogenous production of IL-1 receptor antagonist
(IL-1ra) induced by IL-1beta in chondrocytes, while CloF
alone had no effect. The mechanism of action of CloF
effects was then explored in detail on IL-1ra gene expres-
sion. In transiently transfected chondrocytes, IL1beta-in-
duced p1680 IL-1ra-Luciferase activity was enhanced by
addition of CloF in a dose-dependent manner, indicating a
transcriptional effect. Moreover, chondrocytes co-trans-
fected with p1680 IL-1ra-Luc and a wild-type PPAR-alpha
showed an enhanced response to CloF treatment in
the presence of IL-1beta, while co-transfection with a
dominant negative PPAR-alpha led to the loss of CloF
effect. Two PPAR responsive elements (PPRE) were identi-
fied in the IL-1ra promoter, with binding activity to
PPAR-alpha in vitro (EMSA). Mutations of this PPRE
sites suppressed CloF stimulatory effects. Our data
support a new PPAR-alpha-dependent inhibitory mechan-
ism on IL-1beta-induced gene expression, which might
act through maximization of IL-1ra production in
chondrocytes.
Congress abstracts
Mediators of Inflammation Vol 13  2004 59A peroxysome proliferator-activated receptor gamma-dependent pathway mediates
rosiglitazone inhibition of cytokine-induced metalloproteinase 1 expression in articular
cartilage cells
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Cytokines, such as interleukin-1beta (IL-1beta), induce
cartilage degradation via metalloproteinase (MMP) gene
expression by chondrocytes. We used Rosiglitazone (Rtz) to
assess the influence of peroxysome proliferator-activated
receptor gamma (PPAR-gamma) on IL-1beta-mediated reg-
ulations. We showed, using immunocytochemistry, electro-
phoretic mobility shift assay (EMSA) and transient
transfection assays, that PPAR-gamma was expressed and
functional in chondrocytes in vitro. Rtz displayed differ-
ential concentration-dependent effects. At 10 mM, Rtz
inhibited IL-1beta-induced NO production and COX2
mRNA expression. Rtz also inhibited IL-1beta-induced
decrease in
35S-sulfated proteoglycan production and
gelatinolytic activities, and down-regulated MMP mRNA
expression. When used at concentrations closer to Kd
values, Rtz did not modify NO production nor COX2 mRNA
expression, whereas it maintained its anticytokine effects
on proteoglycan production and MMP gene expression.
The mechanism of action of Rtz anti-IL1beta effect was then
explored on MMP1 gene expression. In transiently trans-
fected chondrocytes, IL1beta-induced pMMP1-Luciferase
activity was inhibited by low concentrations of Rtz,
indicating a transcriptional effect. EMSA analysis showed
that Rtz did not modify IL-1beta-induced NF-kB complex
binding at cognate DNA sites while AP-1 binding was
reduced. The inhibitory effect of Rtz was PPAR-gamma
dependent since it was increased by overexpression of
wild-type PPAR-gamma and suppressed by a dominant
negative PPAR-gamma. A PPAR responsive element
(PPRE) was identified in the MMP1 promoter. Mutations
of this PPRE site suppressed Rtz inhibitory effects. Our data
support a new PPAR-gamma-dependent inhibitory
mechanism on IL-1b-induced MMP1 expression, which
acts through a composite PPRE/AP-1 site at a position
( /83 to  /71) upstream from the transcription start site.
ACKNOWLEDGEMENT. The authors thank the Association
de Recherche sur la Polyarthrite (ARP).
The PPARg agonist pioglitazone reduces inflammation and Ab1 42 levels in APP V717I
transgenic mice
Michael T. Heneka, Magdalena Sastre, Lucia Dumitrescu-Ozimek, Anne Kreutz, Ilse Dewachter, Kerry O’Banion,
Thomas Klockgether, Fred Van Leuven and Gary E. Landreth
Department of Neurology, University of Bonn, Bonn, Germany
Alzheimer’s disease (AD) is characterized by deposition of
b-amyloid in the brain and an associated glia-mediated
inflammatory response. Non-steroidal anti-inflammatory
drugs (NSAIDs) dramatically reduce AD risk and micro-
glial reactivity. NSAIDs bind to and activate the nuclear
receptor peroxisome proliferator-activated receptor g
(PPARg), which acts to inhibit the expression of pro-
inflammatory genes. Recent in vitro data suggested that
NSAIDs negatively regulate immunostimulated APP pro-
cessing via PPARg activation. In line with this result, we
show that an oral seven day treatment of 10-month-old
APP-V717I mice with the PPARg-specific agonist pioglita-
zone or the NSAID ibuprofen resulted in a reduction of
activated microglia and reactive astrocytes in the hippo-
campus and cortex. Drug treatment reduced the expres-
sion of the inflammatory markers COX2 and iNOS. In
parallel with the suppression of inflammatory markers,
pioglitazone and ibuprofen administration decreased
BACE-1 mRNA, protein and activity, and led to a
significant reduction of focal Ab1 42 deposits in the
hippocampus and cortex. Furthermore, treatment with
pioglitazone decreased the levels of soluble Ab1 42
peptide by 27%. These findings demonstrate that anti-
inflammatory drugs and PPARg agonists inhibit inflamma-
tory responses in the brain and modulate amyloi-
dogenesis.
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Peroxisomal proliferator-activated receptors (PPARs)
belong to the superfamily of nuclear receptors and act as
ligand-activated transcription factors. The PPARg isoform is
expressed in human T lymphocytes, and oral administra-
tion of PPARg agonists ameliorates the clinical course and
histopathological features of experimental autoimmune
encephalomyelitis, an animal model for multiple sclerosis
(MS), suggesting a potential role for PPARg agonists in the
treatment of MS. In order to assess a potential therapeutic
role of PPARg agonists in MS, we compared the immuno-
modulatory effects of the thiazolidinediones (TZD), piogli-
tazone and ciglitazone, and the non-TZD agonist
GW347845 on human T-leukemia cells (Jurkat cells)
and phytohemagglutinin-stimulated peripheral blood
mononuclear cells (PBMCs) derived from 21 MS patients
and 12 healthy controls. Pioglitazone, ciglitazone and
GW347845 suppressed PHA-induced T-cell proliferation
and secretion of interferon-g and tumor necrosis factor-a.
Inhibition of proliferation and proinflammatory cytokine
secretion was more pronounced when PBMCs were first
pre-incubated with PPARg-agonists and re-exposed at the
time of PHA stimulation, indicating a sensitizing effect of
PPARg agonists. In order to assess the molecular mechan-
isms of PPARg-mediated anti-inflammatory effects, we
analyzed the PPARg expression levels in PBMCs of MS
patients and healthy controls. Surprisingly, all patients
exhibited decreased PPARg expression levels compared
with controls, and PHA stimulation of PBMCs in healthy
controls resulted in a significant decrease of PPARg
expression. Pre-incubation of PBMCs with PPARg agonists
almost completely prevented this inflammation-induced
decrease in PPARg expression, suggesting that the
anti-inflammatory and antiproliferative effects of PPARg
agonists may result at least in part from an inhibition
of inflammation-induced decrease of PPARg expression
levels.
PPAR beta has an important role in promoting preservation of kidney function during
acute ischemic renal failure
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Epithelial cells from the proximal tubule express both PPAR
alpha and PPAR beta. In ischemic acute renal failure, PPAR
alpha expression and activation afford a protection against
necrosis process. Whether PPAR beta exerts a similar role is
still unknown. To answer this question, we analyzed the
renal dysfunction and injury caused in mice by 30 min
ischemia and 24/48 h reperfusion, using both a pharmaco-
logical and a genetic approach. Administration of the
specific PPAR beta agonist L-165 041 limited tubular
necrosis and protected kidney function as evidenced by a
significant decrease in plasma creatinine levels (26.09 /2.1
versus 44.49 /6.4 mM). Conversely, PPAR beta
 /  and PPAR
beta
 /  mice exhibited significantly greater kidney dys-
function, as assessed by enhanced tubular apoptosis/
necrosis and higher plasma creatinine levels (88.09 /12.5
and 70.39 /10.5, respectively versus 39.59 /5.8 mM). To
identify the mechanisms whereby PPAR beta exerts a
cytoprotection, we analyzed in vitro epithelial cells from
proximal tubule (HK-2 cells) exposed to different
PPAR beta ligands. Neither L-165 041 nor cPGI2 (0.03 /1
mM) affected cell proliferation and viability under
control conditions, but both PPAR beta ligands protected
HK-2 cells from oxidative stress (0.5 mM H2O2 for 24 h)
in a dose-dependent manner. This response involved
the control of Akt signaling since: (1) L-165 041 increased
phosphorylated Akt cell content and (2) L-165 041 effect
on HK-2 cell apoptosis/necrosis was completely prevented
by the addition of Akt inhibitor. In conclusion, the
present study demonstrates that PPAR beta is potentially
involved in the repair process of tubular epithelium.
This role involves antiapoptotic signals, including Akt
activation.
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Conjugated linoleic acid (CLA), a dietary fatty acid, is a
natural ligand for peroxisome proliferator-activated recep-
tors (PPARs). Increasingly, CLA has received considerable
attention due to its important anti-tumour and anti-inflam-
matory effects. CLA is a mixture of mainly cis-9, trans-11
and trans-10, cis-12 isomers and these species are known to
bind to both PPAR-alpha and gamma. It has also been
observed that PPARs have an important role in regulating
the inflammatory response in monocytic cells treated with
advanced glycosylated end-products (AGEs). We have
previously shown in the human monocytic cell line
Monomac 6 (MM6), that incubation of CLA at a concentra-
tion of 60 mM, for 3 and 24 h, was able to significantly
suppress AGE-induced secretion of the inflammatory
cytokines, TNF-a and IL-1b. We therefore suspected that
CLA may be able to affect (AGE) induced inflammatory
activity by regulating RAGE expression. MM6 cells were
treated with CLA at 60 mM for 3 and 24 h and their RAGE
expression determined by western blotting. After 3 h
incubation with CLA, RAGE expression in MM6 cells was
reduced by 22% (range 18 /26%), and by 26% after 24 h
(range 22 /30%), as compared with cells not treated with
CLA. This reduction in RAGE expression was found to be
significant (p B/0.01) when the data was analysed by
ANOVA. The mechanism by which CLA down-regulates
RAGE has not been fully elucidated, but may be in part due
to its PPAR ligand properties of this fatty acid. Furthermore,
these processes may be important in regulating inflamma-
tion in monocytic cells.
Anti-inflammatory effects of peroxysome proliferator-activated receptor gamma in
CCl4-induced hepatitis
Mathilde Malapel
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Introduction: PPAR gamma is a nuclear receptor mainly
expressed in colon and fat adipose tissue. It controls many
physiologic processes such as lipid storage, glucid meta-
bolism and inflammation through regulation of inflamma-
tory cytokine production and inhibition of the NF-kB
pathway. The levels of PPAR gamma in the liver remain
still unknown and the potential anti-inflammatory effects of
PPAR gamma activators in vivo in the liver have not yet
been investigated.
Aim and methods: To quantify PPAR gamma mRNA levels
in different human tissues and to evaluate the involvement
of PPAR gamma in a murine model of CCl4-induced acute
hepatitis (1 ml/kg). PPAR gamma was quantified by
quantitative PCR in human blood mononuclear cells,
pancreas, ileum, skin, liver kidney, colon and adipose
tissues. We tested whether PPAR gamma heterozygous mice
(PPAR gamma
 / ) were more sensitive to CCl4-induced
liver damage than wild type littermates (WT). We also
evaluated the anti-inflammatory effects of a PPAR gamma
agonist (pioglitazone, 50 mg/kg/day) administered preven-
tively 2 days before hepatitis induction in Balb/c mice. The
severity of hepatitis was assessed by mortality rates and
evaluation of histologic lesions using the necro-inflamma-
tory score (Ishak score).
Results: PPAR gamma mRNA were highly expressed in
human liver at similar levels to kidney and skin. Compared
with wild type animals, PPAR gamma
 /  mice displayed a
significantly enhanced susceptibility to CCl4-induced acute
hepatitis, reflected by intense hepatic lesions (10.6 versus 4)
leading to a 50% mortality rate 2 days after CCl4 adminis-
tration. Similar results were provided using the PPAR
gamma activator pioglitazone, which reduced significantly
the mortality rate and the liver injury in treated mice
compared with untreated mice with hepatitis.
Conclusion: This study demonstrates that PPAR gamma is
highly expressed in human liver and is a new factor
involved in the regulation of hepatic inflammation. These
data suggest that PPAR gamma activators may be use as
new therapeutic agents in liver injury.
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The therapeutic protocol for head and neck cancer
requires, in most cases, surgical exeresis of the neoplasm.
This procedure can determine serious functional and
aesthetic alterations, and it must be followed by recon-
structive surgery, using a skin graft. Since reconstructive
surgery can restore only a part of the anatomical defect,
implant methods are of fundamental importance in restor-
ing entirely it. However, intraoral implants surrounded by
skin graft tissue have a low percentage of success, for
inflammation processes and rejection of the implant. Our
research examined in vivo, on biopsies of skin present
around the implants, the modifications of cytokine and
PPAR content in order to find substance(s) able to reduce
the inflammation process improving the implant success. In
the patients showing implant failure, an increase of pro-
inflammatory cytokines (TNFa, IL-1b, IL-6, IL-8) was
evident, coupled with an increase of PPARb expression.
This observation was confirmed in vitro by treating
cultured normal epithelial cells (NCTC 2544) with lipopo-
lysaccharide. Studies investigating the effect of conjugated
linoleic acid, a PPAR ligand, on the content of cytokines and
PPAR are currently being carried out on NCTC 2544
cells and fibroblasts isolated from the same biopsies
used to determine the cytokine content. Preliminary data
on fibroblasts showed that conjugated linoleic acid is
able to reduce the content of pro-inflammatory cytokine,
IL-b.
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15d-PGJ2 inhibits IL-1beta-induced PGE2 production in chondrocytes via a
PPARgamma-independent pathway
Ve ´ronique Meynier de Salinelles
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The cyclopentenone 15-deoxy-D12,14-prostaglandin J2
(15d-PGJ2) has been shown to have anti-inflammatory
effects in different models. Prostaglandin E2 (PGE2) is
involved in many biological processes and is overproduced
in inflammatory conditions. The pro-inflammatory inter-
leukin-1beta (IL-1beta) is a potent mediator of cartilage
degradation and increases PGE2 production, partly through
inducing secreted phospholipase A2 type IIA (sPLA2 IIA)
and cyclooxygenase-2 (COX-2) expressions in chondro-
cyte. In this study, we investigated whether 15d-PGJ2 was
able to inhibit IL-1beta-stimulated PGE2 production and
type 1 microsomal PGE2 synthase (mPGES-1) in human
chondrocytes. 15d-PGJ2, at the micromolar level, sup-
pressed PGE2 production in a time-dependent and dose-
dependent manner, both in rabbit primary cultured
chondrocytes and in T/C28a2 human chondrocyte cell line.
RT-PCR showed that, in the T/C28a2, mPGES-1 expression
was stimulated by IL-1beta and that 15d-PGJ2 inhibited
this IL-1beta-induced expression. We also provide
evidence that 15d-PGJ2 effect is independent from peroxy-
some proliferator-activated receptor g (PPARg) activation
since rosiglitazone, a ligand for PPARg, was unable to
inhibit IL-1beta-induced mPGES-1 expression. Moreover,
we show that 15d-PGJ2 reduced IL-1beta-stimulated
sPLA2-IIA activity, suggesting that 15d-PGJ2 would
also have the ability to decrease the quantity of AA
provided to the COX-2/mPGES-1 enzymatic pathway.
Taken together, these results suggest that 15d-PGJ2 at
pharmacological concentration should have anti-
inflammatory and/or anti-degradative properties in
arthritic conditions such as osteoarthritis or rheumatoid
arthritis.
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The three peroxisome proliferator-activated receptor
(PPAR) subtypes a, b (or d), and g belong to the group of
nuclear receptors that act as ligand-activated transcription
factors. Recently, expression of PPARa and PPARg in
keratinocytes has been demonstrated, and ligands of PPARa
and PPARg were found to enhance epidermal maturation
and protect against cutaneous inflammation. There is first
evidence for a possible role of PPARs in psoriasis, as
expression of PPARa and PPARg is decreased in lesional
skin and treatment with PPARg agonists improves psoriatic
keratinocyte pathology in vitro and in vivo. We performed
a case /control study to search for possible associations
between variations in the genes encoding PPARa and
PPARg and psoriasis. Seven variations in these genes were
analyzed in 192 patients with chronic plaque-type psoriasis
and 330 healthy controls by PCR-based methods. No
association between any of the investigated PPAR variants
and psoriasis was found. Our findings argue against a
significant contribution of the investigated PPAR variations
to the genetic basis of psoriasis.
PPAR-alpha decreases airway inflammation in a model of asthma
Carine Orthez
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We have addressed the role of PPAR-alpha in inflammation
associated with asthma using both PPAR-alpha
 /  versus
PPAR-alpha
 /  mice, and mice treated with PPAR-alpha
agonists. Naive PPAR alpha
 /  mice exhibited no differ-
ence in total and differential cell counts in bronchoalveolar
lavage (BAL) fluids, as compared with PPAR-alpha
 / 
animals. Histological examination of their airways con-
firmed the absence of inflammation, and showed no tissue
remodeling. Upon allergen sensitization and challenge with
ovalbumin (OA), PPAR-alpha
 /  mice displayed, how-
ever, increased total cell number and eosinophilia (1.6-fold
and 2.1-fold, respectively, p B/0.05) in BAL fluids, and
greater peribronchial and perivascular eosinophil infiltrates
in tissue, as compared with sensitized and challenged
PPAR-alpha
 /  animals. PPAR-alpha
 /  mice also exhib-
ited increased levels of the pro-inflammatory cytokines
TNF-a and IL-5 (1.9-fold and 1.8-fold, respectively) in BAL
fluids. Conversely, allergen sensitized and challenged
C57BL/6 mice treated with the PPAR-alpha agonist, fenofi-
brate (5 /500 mg/kg, p.o.) displayed a dose-dependent
decrease in total cells and eosinophilia in BAL fluids. BAL
eosinophilia was also significantly reduced in mice that
received another fibrate, ciprofibrate. In animals treated
with 500 mg/kg fenofibrate, reduction in eosinophilia
reached 70% (p B/0.001), as compared with 90% in mice
treated with dexamethasone (5 mg/kg p.o.). Levels of TNF-
a and IL-5 in BAL fluids were also significantly reduced (by
63% and 46%, respectively). Our data provide evidence of a
beneficial and potent effect of PPAR-alpha activation on
airway inflammation associated with asthma.
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Human implantation involves a major invasion of the
uterine wall and remodelling of the uterine arteries by
trophoblastic cells. Abnormalities in these early steps of
placental development lead to placental ischemia, foetal
growth defects, and are frequently associated with pre-
eclampsia, a serious disease specific to human pregnancy.
Lipid metabolism is altered during normal human preg-
nancy, with low-density lipoproteins (LDL) becoming more
susceptible to oxidation. The aim of this study was to
localize oxidized LDL (oxLDL) at the implantation site and
to investigate the role of oxLDL in human trophoblast
invasion in vitro. We showed by immunohistochemistry
that oxLDL was present in trophoblastic cells involved in
invasion. Incubation of these primary invasive cells with
oxLDL showed a concentration-dependent inhibition in
cell invasion, whereas non-oxidized LDL had no effect.
oxLDL-mediated effect was abrogated by pre-incubation
of cells with a pan-RXR antagonist. These results and our
recent report that PPARg is involved in the control of
trophoblast invasion suggest that human trophoblastic
cell invasion may be modulated by oxLDL in vivo
through activation of PPARg/RXR heterodimers, and
provide new insights into the pathophysiology of
pre-eclampsia associated with oxidative stress,
excessive lipid peroxidation and defective trophoblast
invasion.
Multiple mechanisms involved in the effects of the PPAR agonist
15-deoxy-Delta12,14-prostaglandin J2 in mesangial cells
Francisco J. Sa `nchez-Go `mez, Eva Cernuda-Morollo `n, Konstantinos Stamatakis and Dolores Pe ´rez-Sala
Departamento de Estructura y Funcio `n de Proteı `nas, Centro de Investigaciones Biolo `gicas, C.S.I.C.,
Ramiro de Maeztu, 9, 28040 Madrid, Spain
Mesangial cells (MC) are key players in the inflammatory
and proliferative diseases of the renal glomerulus. These
cells express PPARalpha, beta and gamma forms, and
agonists of these receptors have been shown to modulate
the response of mesangial cells to pro-inflammatory stimuli.
We have observed that cytokine stimulation of MC in-
creases the generation of prostaglandins of the J series, like
15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2), as de-
tected by enzyme immunoassay of the cell culture super-
natants. The increase of 15d-PGJ2 is delayed with respect to
the onset of COX-2 expression and is inhibited by
indomethacin. 15d-PGJ2 is an agonist of the transcription
factor PPARgamma as well as a reactive electrophile due to
its cyclopentenone structure. Incubation of MC in the
presence of 15d-PGJ2 at concentrations above 1 micro-
molar leads to the activation of PPAR, as measured with a
PPRE reporter construct, and increases the expression of
PPAR target genes. In addition, 15d-PGJ2 forms covalent
adducts with a number of cellular proteins distributed both
in nuclear and cytosolic compartments. Protein modifica-
tion by exogenous 15d-PGJ2 can be detected using
nanomolar concentrations of a biotinylated 15d-PGJ2
analog. Covalent binding of 15d-PGJ2 to cellular proteins
may modulate transcription factor activity by direct or
indirect mechanisms. We have observed that 15d-PGJ2
directly binds to components of NF-kappaB and AP-1
transcription factors, an effect that is associated with
inhibition of DNA binding. The contribution of these
various mechanisms to the modulation of gene expression
in MC will be discussed.
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Peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors regulating genes involved in lipid and
glucose metabolism. PPARa and PPARg are expressed in
macrophages where they control inflammation and choles-
terol homeostasis. Since macrophages have the ability to
generate reactive oxygen species (ROS), the aim of this
study was to investigate whether PPARa or PPARg influence
the production of hydrogen peroxide, a marker of ROS, in
macrophages. An increase in the production of H2O2,
measured using dichlorofluorescein fluorescence, was ob-
served in THP-1 monocytes, primary human macrophages,
as well as in murine bone marrow-derived, peritoneal and
Raw 264.7 macrophages, incubated with different PPARa
but not with PPARg agonists. PPARa activation did not
induce cellular toxicity, oxidation of the cellular membrane
nor ATP depletion. However, after 24 h a large decrease in
intracellular glutathione levels was observed after treatment
with PPARa ligands. The increase in H2O2 production was
not due to inherent pro-oxidant effects of the PPARa
agonists tested, but was mediated by PPARa since the
effects were lost in bone marrow-derived macrophages
from PPARa-deficient mice. The induction of H2O2 by
PPARa is mediated by NADPH oxidase, since (1) preincu-
bation with the NADPH oxidase inhibitor diphenyleneio-
dinium prevented the increase in H2O2 production; (2)
PPARa agonists induce mRNA levels of the NADPH oxidase
subunits p47
phox, p67
phox and gp91
phox; and (3) induction
of H2O2 production is abolished in p47
phox subunit-
deficient mice. In conclusion, PPARa but not PPARg gene
activation stimulates H2O2 production via NADPH oxidase
in macrophages, which results in the modification of the
redox status.
Peroxisome proliferator-activated receptor-g (PPARg) agonists modulate
immunostimulated processing of APP through regulation of b-secretase (BACE)
Magdalena Sastre, Ilse Dewachter, Evan Rosen, Gary Landreth, Timothy M. Willson, Thomas Klockgether,
Fred van Leuven and Michael T. Heneka
Department of Neurology, University of Bonn, Bonn, Germany
Prolonged intake of non-steroidal anti-inflammatory drugs
(NSAIDs) reduces the risk for Alzheimer’s disease (AD). To
determine the mechanisms by which inflammation affects
AD and how NSAIDs protect against it, we stimulated N2a
neuroblastoma cells stably transfected with amyloid pre-
cusor protein (APP) with pro-inflammatory cytokines,
which increased the secretion of amyloid-b (Ab) and APP
ectodomain. Addition of ibuprofen, indomethacin, peroxi-
some proliferator-activated receptor-g (PPARg) agonists or
cotransfection with PPARg cDNA reversed this effect. The
inhibitory action of ibuprofen and indomethacin was
supressed by PPARg antagonists. We observed that the
mRNA levels, expression and enzymatic activity of
b-secretase (BACE) were increased by immuno-
stimulation and normalized by NSAIDs. We performed
the same experiments using mouse embryonic fibroblasts
from PPARg knockout mice and N2a cells transfected
with siRNA for PPARg. In these conditions, we did not
find modulation of BACE by inflammation and
ibuprofen. In conclusion, pro-inflammatory cytokines acti-
vate b-secretase and NSAIDs inhibit that effect through
PPARg.
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In this study, we examined the effect of phytanic acid and
BRL49653 on gene expression of inflammatory markers in
adipose tissue in mice with diet-induced obesity.
Forty-eight male C57BL/6J mice were assigned to four
groups (n /12/group). One group received chow
(lean control [LC]), while three groups received a high-fat
(HF) diet. One of the HF groups served as the fat control
(FC), whereas the other two received additionally either
phytanic acid at 150 mpk or BRL49653 at 10 mpk
(TZD). Mice receiving HF became obese and diabetic
during the study period. After 23 weeks, epididymal
adipose tissue was collected from six mice per group and
analyzed using Affymetrix Genechip. Genes known to be
involved in inflammatory responses were selected and
further filtered to include only those with change factors
B/ /0.5 or  /0.5 and p B/0.05. The HF diet resulted in
upregulation of the acute-phase proteins haptoglobin, and
orosomucoid 1 and 2, the lipopolysaccharide (LPS) binding
protein, and heat-shock protein (HSP) 72. Treatment with
either PPARgamma agonist resulted in a downregulation of
the expression of most of these markers to levels close to
LC. Other classical inflammatory markers were not regu-
lated.
Our results suggest that the obesity-induced persistent
acute-phase reaction in adipose tissue can drastically be
reduced by treatment with either phytanic acid or
BRL49653.
Apoptosis and G1-arrest of human renal interstitial fibroblast cells induced by
PPAR-gamma activation
Weiming Wang, Jiayun Chen, Feng Liu and Nan Chen
Department of Nephrology, Ruijin Hopital, Shanghai Second Medical University, Shanghai 200025, P.R. China
The peroxisome proliferators activated receptors (PPARs)
are a ligand activated transcription factor superfamily
regulating cellular proliferation and apoptosis. PPAR-gam-
ma-mediated signals play an important role in ameliorate
inflammation and fibrosis. The aim of this study is to
investigate the effect of PPAR-gamma agonists on human
renal interstitial fibroblast (HFB).
Methods: HFB were treated with ligands for PPAR-gamma:
15d-PGJ2 (50 mM), and its agonists troglitazone (50 mM) and
ciglitazone (10 mM) for different times (24-72 h). The cell
viability was measured by trypan blue exclusion. Cell
apoptosis were assessed by flow cytometry using annexin
V/propidium iodide. The cell cycle was determined by flow
cytometry.
Results: When HFB were exposed to PPAR-gamma agonists,
the cellular viabilities are much lower than the control
group (p B/0.05). All PPAR-gamma agonists induced more
cell apoptosis compared with the control group (15d-PGJ2,
16.84%; ciglitazone, 14.78%; and troglitazone, 11.26%
versus control, 3.49%; p B/0.01, p B/0.01, and p B/0.05,
respectively) and increased the percentage of G0/G1 cells.
Conclusion: We conclude that PPAR-gamma agonists can
increase cell death by inducing the apoptosis of HFB and
inhibit the cellular proliferation by G1-arrest. Thus, PPAR-
gamma can be a potential target for new therapeutic
approaches in the renal interstitial fibrosis.
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